MicroPulse Transscleral Laser Therapy and Its Short-term Impact on Ocular Surface

NACompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 3, 2023

Primary Completion Date

October 31, 2023

Study Completion Date

October 31, 2023

Conditions
ConjunctivaCornea
Interventions
PROCEDURE

conjunctival biopsy after micropulse transscleral laser therapy

"During MicroPulse TLT, all patients received periocular anesthesia, with an injection of 5 to 10 ml of Lidocaine (Xylocaine 5mg/ml ®) to achieve complete anesthesia.~The investigators employed the 810 nm Cyclo G6® Laser in its MicroPulse® mode (Iridex Corporation, Mountain View, CA, USA) and delivered laser energy to the eye using the second-generation MicroPulse P3® probe (Iridex Corporation, Mountain View, CA, USA). The laser was calibrated to generate a power output of 2500 mW, and a MicroPulse duty cycle of 31.3%. The curved end of the probe's footplate (bunny ears) was positioned 0.5 to 1 mm away from the corneoscleral limbus, maintaining a perpendicular orientation to the eyeball.~Following the laser therapy, an immediate conjunctival biopsy measuring 2 \* 2 mm and avoiding the laser-treated region was performed."

Trial Locations (1)

8000

Mohamed Taher Maamouri Hospital, Nabeul

All Listed Sponsors
lead

University Tunis El Manar

OTHER

NCT06353776 - MicroPulse Transscleral Laser Therapy and Its Short-term Impact on Ocular Surface | Biotech Hunter | Biotech Hunter